Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q1 FY2023 Earnings Presentation
18 slides from Glenmark Pharmaceuticals's earnings presentation, Aug 10, 2022
Slide 1: Investor Presentation Q1 FY 2022-23
Presentation Heading or Sub Heading INVESTOR PRESENTATION Q1 FY 2022-23 10 August 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Glenmark Pharmaceuticals Ltd. The information, statements and analysis made in this presentation describing Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. These statements are based on current expec
Slide 3: Corporate Overview
Corporate Overview Glenmark operates its businesses through three GPL is primarily focused on building a separate entities. Glenmark global Generics, Specialty and OTC Pharmaceuticals business in the therapy areas of Ltd. (GPL) Dermatology, Respiratory and Oncology www.glenmarkpharma.com Glenmark Li
Slide 4: Q1 FY2023 Snapshot
Q1 FY2023 Snapshot • Revenues from Operations at Rs. 27,773 Mn down -6.3% YoY; excluding global sales of Covid-related products, YoY growth in Q1 FY23 at 10.4% • Adjusted EBITDA1 of Rs. 4,726 Mn with EBITDA margin of 17% • Reported PAT of Rs. 2,111 Mn Consolidated Revenue of Rs. 27,773 Mn; decrease
Slide 5: Consolidated Revenues from Operations
Consolidated Revenues from Operations First Quarter ended June 30 Fourth Quarter ended March 31 YoY Growth QoQ Growth Rs Mn FY 2022-23 FY 2021-22 FY 2021-22 (%) (%) India 10,352 12,250 -15.5% 8,847 17.0% North America 6,628 7,878 -15.9% 7,378 -10.2% Europe 3,300 3,059 7.9% 4,968 -33.6% Rest of the W
Slide 6: Revenue distribution by key geographies
Revenue distribution by key geographies 10% 0% 11% 1% 12% 0% 12% 29% 15% 37% 41% 18% 10% Q1FY22 Q4FY22 Q1FY23 12% 17% 24% 27% 24% India Europe API North America ROW Other Revenue 6
Slide 7: P&L Highlights
P&L Highlights Rs. Mn 1Q FY23 1Q FY22 %YoY 4Q FY22 %QoQ Revenues from Operations 27,773 29,649 -6.3% 30,191 -8.0% 1 EBITDA 4,316 5,736 -24.8% 4,634 -6.9% EBITDA margin (%) 15.5% 19.3% 15.3% Other Income (exp) 1,832 586 212.7% 1,072 70.9% 2 -- Exceptional gain (loss) -- -825 Profit Before Tax (PBT) 4
Slide 8: India Formulations
37% India Formulations Strong performance QoQ growth of 17% in Increased ranking to 5th across core brands in base business in the Cardiac segment Glenmark Consumer Care YoY: -15.5% Key Highlights Revenue (INR Mn) QoQ: 17.0% • Sales of Rs. 10,352 Mn recording decline of -15.5% YoY; decline is on acc
Slide 9: North America
North America 24% Acquired 5 approved OTC Plan to file 12-15 ANDAs 176 products authorized ANDAs from Wockhardt in FY23 to distribute in Q1 FY23 YoY: -15.9% Revenue (INR Mn) QoQ: -10.2% Key Highlights 7,878 • Sales of Rs. 6,628 Mn recording decline of -10.2% QoQ 7,378 6,628 • Granted PAS final appro
Slide 10: Europe
Europe 12% Poland and Czech key Steady growth across Multiple product growth markets in CEE Western Europe markets launches across markets for Q1 YoY: 7.9% Revenue (INR Mn) QoQ: -33.6% Key Highlights 4,968 • Sales of Rs. 3,300 Mn recording growth of 7.9% YoY • Steady growth in both key markets of We
Slide 11: ROW (Asia, MEA, LATAM and RCIS regions)
15% ROW (Asia, MEA, LATAM and RCIS regions) Impact of economic Asia, MEA region YoY growth of 25.8% sanctions in Russia on recorded strong primary sales in Q1 secondary sales growth YoY: 25.8% Revenue (INR Mn) QoQ: -22.9% Key Highlights 5,479 • Sales of Rs. 4,226 Mn recording growth of 25.8% YoY • R
Slide 12: API business (Glenmark Life Sciences)
12% API business (Glenmark Life Sciences) Received EC for 1,000 KL Overall GLS sales at Rs. Overall GLS EBITDA capacity greenfield plant 4,899 Mn margin at 31.9% at Solapur YoY: 6.9% Revenue (INR Mn) QoQ: -1.0% Key Highlights 3,251 3,283 • External sales of API were at Rs. 3,251 Mn, recording growth
Slide 13: Respiratory Strategy – Creating Global Scale
Respiratory Strategy – Creating Global Scale • During the first quarter, Glenmark received Marketing Authorization (MA) grants for Ryaltris in Singapore and Bahrain. Company awaiting regulatory approvals for its filings in Canada, Brazil, Malaysia, and several other emerging markets • Glenmark’s par
Slide 14: Innovative R&D Pipeline
Innovative R&D Pipeline GRC 17536 • GLP toxicology studies for metabolite qualification were completed last year TRPA1 antagonist • The GRC 17536 Phase 2b study was initiated in Q2 FY22 and is currently ongoing in India with interim data for Painful diabetic peripheral futility analyses is expected
Slide 15: Ichnos Sciences is a Clinical-Stage Biotechnology Company
Ichnos Sciences is a Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology • Global footprint: U.S. and Switzerland Fully Integrated • Fully owned by Glenmark, with plans to expand the investor base in the future Biotech • Accomplished management team with proven track reco
Slide 16: Ichnos is Advancing a Differentiated Pipeline
Ichnos is Advancing a Differentiated Pipeline with Potential First – and Best-in-Class Assets Ichnos Oncology Pipeline - First Wave Focuses on T-Cell Ichnos to Out-License Assets in Autoimmune (AI) Disease Engagers and Macrophage Modulators Molecule Molecule Potential Phase/Status Lead Indication Me
Slide 17: Key Objectives of Financial Year 2022-23
Key Objectives of Financial Year 2022-23 1 Revenue growth of 6-8% during the year 2 Sustain EBITDA margin performance at similar levels of FY22 3 Strategic priority to enhance free cash generation for further debt reduction 4 Capex of Rs. 7-8 Bn 5 Close 1-2 out-licensing agreements in our innovation
Slide 18: Thank You
Thank You www.glenmarkpharma.com
Glenmark Pharmaceuticals — Q1 FY2023 Earnings Presentation on 6ix